Back to search results

Study on Fasting and GLP-1 Medications for Obesity

This study is looking at how long you fast (don't eat) and temporarily stopping certain medications (liraglutide, oral semaglutide, or injected semaglutide) affect how much food is left in your stomach. It's for people with obesity, aged 18 or older, with a BMI between 25 and 45. Some participants may also have type 2 diabetes. The main goal is to see if your stomach is empty after fasting for different lengths of time following a high-fat meal, while taking these medications. The study aims to enroll 71 people, but its current status is unclear.

Study design
This is an interventional study, meaning participants will receive specific treatments. It plans to enroll 71 participants.
What's involved
The length of your participation will depend on which GLP-1 medication you are already using. You will have multiple visits where your stomach emptying will be measured at various times after fasting.
Compensation
Not stated in the trial record.
Follow-up
Your stomach emptying will be measured up to 24 hours after starting fasting on specific study days (Day 40, Day 161, or Day 141), depending on the medication group.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.

NCT07225816

Examination of How the Duration of Fasting and Temporary Stopping of GLP-1 Medications Affect the Amount of Food Left in the Stomach in People Using Liraglutide (Injected), Semaglutide (Taken by Mouth) or Semaglutide (Injected)

Recruiting
PHASE1Ages 18+InterventionalTreatment
Novo Nordisk A/S
~71 participants
Updated 2026-07-21 on ClinicalTrials.gov
What's tested:LiraglutideOral SemaglutideSemaglutide

At a glance

Recruiting sites
1 of 1 listed site is recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
Occurrence of empty stomach (antrum grade 0 or 1) after fasting following a solid, high-fat meal after dosing of subcutaneous (s.c.) liraglutide once daily (Yes/No)
Measured over 6, 8, 10, 12, 18 and 24 hours after start of fasting on Visit 7, Day 40
+2 more outcomes measured

Conditions

Obesity

Explore related trials

ObesityType 2 Diabetes Mellitus

Where it's being run

1 sites across 1 states
California1

Study leadership

  • Clinical Transparency (dept. 2834) · STUDY_DIRECTOR · Novo Nordisk A/S

Who to contact

Novo Nordisk
[email protected]
(+1) 866-867-7178
Email the study team

Opens a ready-to-send draft in your own email app — review before sending.

Do you actually qualify for this trial?

Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.

Check eligibility for this trial ~2 min · HIPAA-protected · delete anytime
Eligibility criteria

Inclusion

Male or female.
Age 18 years or above at the time of signing the informed consent.
BMI between 25.0 and 45 kilogram per meter square (kg/m\^2) (both inclusive) at screening. Overweight should be due to excess adipose tissue, as judged by the investigator.
Diagnosed with type 2 diabetes (T2D) more than (\>) 180 days before screening.
Treatment with:

Exclusion

Presence of clinically significant gastrointestinal disorders or symptoms of gastrointestinal disorders potentially affecting absorption of drugs or nutrients, or as judged by the investigator.
History of major surgical procedures involving the oesophagus or stomach potentially affecting absorption of trial products (e.g. subtotal and total gastrectomy, sleeve gastrectomy, gastric bypass surgery) or current presence of gastrointestinal implant.
Diagnosed with or suspected to suffer from clinically significant gastroparesis, hiatal hernia or severe gastro-oesophageal reflux diseases with daily symptoms and/or in supine position.
Use of other medications known to affect the motility of the stomach.
Inability to lie in the right lateral decubitus position for gastric ultrasonography.
Unusual meal habits and special diet requirements or unwillingness to eat the meals provided in the study.
HbA1c ≥ 10.5 % (91 mmol/mol) at screening.
Current treatment with insulin or insulin secretagogues that might increase risk of hypoglycaemia during periods of fasting.
Recurrent severe hypoglycaemia (more than 1 severe hypoglycaemic event within 180 days) or hypoglycaemic unawareness as judged by the investigator or hospitalisation for diabetic ketoacidosis within 180 days before screening

What this trial measures

  • Occurrence of empty stomach (antrum grade 0 or 1) after fasting following a solid, high-fat meal after dosing of subcutaneous (s.c.) liraglutide once daily (Yes/No)6, 8, 10, 12, 18 and 24 hours after start of fasting on Visit 7, Day 40

    Measured as count of participants.

  • Occurrence of empty stomach (antrum grade 0 or 1) after fasting following a solid, high-fat meal after dosing of oral semaglutide once daily (Yes/No)6, 8, 10, 12, 18 and 24 hours after start of fasting on Visit 11, Day 161

    Measured as count of participants.

  • Occurrence of empty stomach (antrum grade 0 or 1) after fasting following a solid, high-fat meal after dosing of s.c. semaglutide once weekly (Yes/No)6, 8, 10, 12, 18 and 24 hours after start of fasting on Visit 7, Day 141

    Measured as count of participants.